(ARE) Alexandria Real Estate - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US0152711091
Stock: Life Science Properties, Real Estate Development, Venture Capital
Total Rating 15
Risk 67
Buy Signal -1.47
| Risk 5d forecast | |
|---|---|
| Volatility | 37.1% |
| Relative Tail Risk | -2.09% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.46 |
| Alpha | -60.08 |
| Character TTM | |
|---|---|
| Beta | 0.639 |
| Beta Downside | 0.932 |
| Drawdowns 3y | |
|---|---|
| Max DD | 62.90% |
| CAGR/Max DD | -0.37 |
EPS (Earnings per Share)
Revenue
Description: ARE Alexandria Real Estate March 03, 2026
Alexandria Real Estate Equities (NYSE: ARE) is a S&P 500-listed REIT that specializes in life-science real estate, operating and developing collaborative “mega-campus” environments across premier innovation clusters such as Greater Boston, the Bay Area, San Diego, Seattle, Maryland, the Research Triangle, and New York City.
As of December 31 2025, the company’s market capitalization stood at roughly $20.75 billion, with a portfolio of 35.9 million rentable square feet (RSF) of operating assets and an additional 3.5 million RSF of Class A/A+ space under construction.
Recent performance metrics show a 96.5 % occupancy rate across its life-science properties, a 5 % year-over-year net rent growth, and a reported FFO of $1.30 per share for Q4 2025, supporting a dividend yield near 3.1 %.
Key sector drivers include robust biotech R&D spending-projected to exceed $250 billion globally in 2026-steady venture-capital inflows into life-science startups, and continued demand for high-spec laboratory and office space, all of which underpin Alexandria’s long-term lease terms and premium rental rates.
Consider digging deeper on ValueRay for more insights.
Headlines to watch out for
- Life science cluster demand drives property occupancy and rental income
- Biotech funding environment impacts tenant growth and leasing
- Interest rate fluctuations influence development costs and property valuations
- Regulatory changes in life science sector affect tenant stability
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income: -1.43b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA 0.14 > 1.0 |
| NWC/Revenue: -41.84% < 20% (prev -38.50%; Δ -3.33% < -1%) |
| CFO/TA 0.04 > 3% & CFO 1.41b > Net Income -1.43b |
| Net Debt (12.21b) to EBITDA (360.4m): 33.88 < 3 |
| Current Ratio: 0.43 > 1.5 & < 3 |
| Outstanding Shares: last quarter (170.4m) vs 12m ago -0.97% < -2% |
| Gross Margin: 68.94% > 18% (prev 0.70%; Δ 6.82k% > 0.5%) |
| Asset Turnover: 8.30% > 50% (prev 8.13%; Δ 0.17% > 0%) |
| Interest Coverage Ratio: -4.37 > 6 (EBITDA TTM 360.4m / Interest Expense TTM 226.7m) |
Altman Z''
| A: -0.04 (Total Current Assets 939.8m - Total Current Liabilities 2.18b) / Total Assets 34.08b |
| B: error (Retained Earnings missing) |
| C: -0.03 (EBIT TTM -990.0m / Avg Total Assets 35.80b) |
| D: -0.00 (Book Value of Equity -27.7m / Total Liabilities 14.93b) |
Beneish M -2.32
| DSRI: 1.97 (Receivables 323.7m/168.5m, Revenue 2.97b/3.05b) |
| GMI: 1.02 (GM 68.94% / 70.19%) |
| AQI: 0.99 (AQ_t 0.94 / AQ_t-1 0.95) |
| SGI: 0.97 (Revenue 2.97b / 3.05b) |
| TATA: -0.08 (NI -1.43b - CFO 1.41b) / TA 34.08b) |
| Beneish M-Score: -2.32 (Cap -4..+1) = BBB |
What is the price of ARE shares?
As of March 23, 2026, the stock is trading at USD 47.39 with a total of 1,561,270 shares traded.
Over the past week, the price has changed by -2.11%, over one month by -11.67%, over three months by -1.09% and over the past year by -47.98%.
Over the past week, the price has changed by -2.11%, over one month by -11.67%, over three months by -1.09% and over the past year by -47.98%.
Is ARE a buy, sell or hold?
Alexandria Real Estate has received a consensus analysts rating of 3.54.
Therefor, it is recommend to hold ARE.
- StrongBuy: 3
- Buy: 1
- Hold: 9
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ARE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 59.6 | 25.8% |
| Analysts Target Price | 59.6 | 25.8% |
ARE Fundamental Data Overview March 21, 2026
P/E Forward = 16.6945
P/S = 2.8446
P/B = 0.5412
P/EG = 3.2356
Revenue TTM = 2.97b USD
EBIT TTM = -990.0m USD
EBITDA TTM = 360.4m USD
Long Term Debt = 12.05b USD (from longTermDebt, last quarter)
Short Term Debt = 353.2m USD (from shortTermDebt, last quarter)
Debt = 12.76b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 12.21b USD (from netDebt column, last quarter)
Enterprise Value = 20.79b USD (8.58b + Debt 12.76b - CCE 549.1m)
Interest Coverage Ratio = -4.37 (Ebit TTM -990.0m / Interest Expense TTM 226.7m)
EV/FCF = 14.71x (Enterprise Value 20.79b / FCF TTM 1.41b)
FCF Yield = 6.80% (FCF TTM 1.41b / Enterprise Value 20.79b)
FCF Margin = 47.60% (FCF TTM 1.41b / Revenue TTM 2.97b)
Net Margin = -48.15% (Net Income TTM -1.43b / Revenue TTM 2.97b)
Gross Margin = 68.94% ((Revenue TTM 2.97b - Cost of Revenue TTM 922.6m) / Revenue TTM)
Gross Margin QoQ = 69.18% (prev 67.49%)
Tobins Q-Ratio = 0.61 (Enterprise Value 20.79b / Total Assets 34.08b)
Interest Expense / Debt = 0.51% (Interest Expense 65.7m / Debt 12.76b)
Taxrate = 21.0% (US default 21%)
NOPAT = -782.1m (EBIT -990.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 0.43 (Total Current Assets 939.8m / Total Current Liabilities 2.18b)
Debt / Equity = 0.82 (Debt 12.76b / totalStockholderEquity, last quarter 15.47b)
Debt / EBITDA = 33.88 (Net Debt 12.21b / EBITDA 360.4m)
Debt / FCF = 8.64 (Net Debt 12.21b / FCF TTM 1.41b)
Total Stockholder Equity = 16.69b (last 4 quarters mean from totalStockholderEquity)
RoA = -4.00% (Net Income -1.43b / Total Assets 34.08b)
RoE = -8.57% (Net Income TTM -1.43b / Total Stockholder Equity 16.69b)
RoCE = -3.45% (EBIT -990.0m / Capital Employed (Equity 16.69b + L.T.Debt 12.05b))
RoIC = -2.63% (negative operating profit) (NOPAT -782.1m / Invested Capital 29.78b)
WACC = 3.57% (E(8.58b)/V(21.34b) * Re(8.27%) + D(12.76b)/V(21.34b) * Rd(0.51%) * (1-Tc(0.21)))
Discount Rate = 8.27% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.21%
[DCF] Terminal Value 83.09% ; FCFF base≈1.45b ; Y1≈1.10b ; Y5≈675.7m
[DCF] Fair Price = 50.38 (EV 20.94b - Net Debt 12.21b = Equity 8.73b / Shares 173.3m; r=5.90% [WACC]; 5y FCF grow -28.40% → 2.90% )
EPS Correlation: -41.06 | EPS CAGR: -70.37% | SUE: -4.0 | # QB: 0
Revenue Correlation: 85.51 | Revenue CAGR: 5.71% | SUE: -2.12 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.09 | Chg7d=+0.046 | Chg30d=+0.049 | Revisions Net=+0 | Analysts=4
EPS current Year (2026-12-31): EPS=0.18 | Chg7d=+0.135 | Chg30d=+0.154 | Revisions Net=+1 | Growth EPS=+102.2% | Growth Revenue=-11.5%
EPS next Year (2027-12-31): EPS=-0.15 | Chg7d=+0.142 | Chg30d=+0.202 | Revisions Net=+0 | Growth EPS=-179.8% | Growth Revenue=+0.8%
[Analyst] Revisions Ratio: +1.00 (1 Up / 0 Down within 30d for Current Year)
P/S = 2.8446
P/B = 0.5412
P/EG = 3.2356
Revenue TTM = 2.97b USD
EBIT TTM = -990.0m USD
EBITDA TTM = 360.4m USD
Long Term Debt = 12.05b USD (from longTermDebt, last quarter)
Short Term Debt = 353.2m USD (from shortTermDebt, last quarter)
Debt = 12.76b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 12.21b USD (from netDebt column, last quarter)
Enterprise Value = 20.79b USD (8.58b + Debt 12.76b - CCE 549.1m)
Interest Coverage Ratio = -4.37 (Ebit TTM -990.0m / Interest Expense TTM 226.7m)
EV/FCF = 14.71x (Enterprise Value 20.79b / FCF TTM 1.41b)
FCF Yield = 6.80% (FCF TTM 1.41b / Enterprise Value 20.79b)
FCF Margin = 47.60% (FCF TTM 1.41b / Revenue TTM 2.97b)
Net Margin = -48.15% (Net Income TTM -1.43b / Revenue TTM 2.97b)
Gross Margin = 68.94% ((Revenue TTM 2.97b - Cost of Revenue TTM 922.6m) / Revenue TTM)
Gross Margin QoQ = 69.18% (prev 67.49%)
Tobins Q-Ratio = 0.61 (Enterprise Value 20.79b / Total Assets 34.08b)
Interest Expense / Debt = 0.51% (Interest Expense 65.7m / Debt 12.76b)
Taxrate = 21.0% (US default 21%)
NOPAT = -782.1m (EBIT -990.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 0.43 (Total Current Assets 939.8m / Total Current Liabilities 2.18b)
Debt / Equity = 0.82 (Debt 12.76b / totalStockholderEquity, last quarter 15.47b)
Debt / EBITDA = 33.88 (Net Debt 12.21b / EBITDA 360.4m)
Debt / FCF = 8.64 (Net Debt 12.21b / FCF TTM 1.41b)
Total Stockholder Equity = 16.69b (last 4 quarters mean from totalStockholderEquity)
RoA = -4.00% (Net Income -1.43b / Total Assets 34.08b)
RoE = -8.57% (Net Income TTM -1.43b / Total Stockholder Equity 16.69b)
RoCE = -3.45% (EBIT -990.0m / Capital Employed (Equity 16.69b + L.T.Debt 12.05b))
RoIC = -2.63% (negative operating profit) (NOPAT -782.1m / Invested Capital 29.78b)
WACC = 3.57% (E(8.58b)/V(21.34b) * Re(8.27%) + D(12.76b)/V(21.34b) * Rd(0.51%) * (1-Tc(0.21)))
Discount Rate = 8.27% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.21%
[DCF] Terminal Value 83.09% ; FCFF base≈1.45b ; Y1≈1.10b ; Y5≈675.7m
[DCF] Fair Price = 50.38 (EV 20.94b - Net Debt 12.21b = Equity 8.73b / Shares 173.3m; r=5.90% [WACC]; 5y FCF grow -28.40% → 2.90% )
EPS Correlation: -41.06 | EPS CAGR: -70.37% | SUE: -4.0 | # QB: 0
Revenue Correlation: 85.51 | Revenue CAGR: 5.71% | SUE: -2.12 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.09 | Chg7d=+0.046 | Chg30d=+0.049 | Revisions Net=+0 | Analysts=4
EPS current Year (2026-12-31): EPS=0.18 | Chg7d=+0.135 | Chg30d=+0.154 | Revisions Net=+1 | Growth EPS=+102.2% | Growth Revenue=-11.5%
EPS next Year (2027-12-31): EPS=-0.15 | Chg7d=+0.142 | Chg30d=+0.202 | Revisions Net=+0 | Growth EPS=-179.8% | Growth Revenue=+0.8%
[Analyst] Revisions Ratio: +1.00 (1 Up / 0 Down within 30d for Current Year)